 Monopar Therapeutics Inc NASDAQ: MNPR has announced the publication of a peer-reviewed study that demonstrated Monopars Urokinase plasminogen activator uPA antibody fragment radiotracer could potentially identify breast cancers with uPA overexpression and monitor uPA activity during treatment using PET imaging. uPA is an established biomarker in current breast cancer clinical practice guidelines, and its presence is used to select appropriate drug treatment. 